A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity.
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
A voltage-gated sodium channel subtype that mediates the sodium ion PERMEABILITY of CARDIOMYOCYTES. Defects in the SCN5A gene, which codes for the alpha subunit of this sodium channel, are associated with a variety of CARDIAC DISEASES that result from loss of sodium channel function.
An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
Ion channels that specifically allow the passage of SODIUM ions. A variety of specific sodium channel subtypes are involved in serving specialized functions such as neuronal signaling, CARDIAC MUSCLE contraction, and KIDNEY function.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.
Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive.
The circulation in a portion of the body of one individual of blood supplied from another individual.
An alkaloid found in the root of RAUWOLFIA SERPENTINA, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
A group of cardiac arrhythmias in which the cardiac contractions are not initiated at the SINOATRIAL NODE. They include both atrial and ventricular premature beats, and are also known as extra or ectopic heartbeats. Their frequency is increased in heart diseases.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Transplantation of an individual's own tissue from one site to another site.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Agents that prevent clotting.
The chambers of the heart, to which the BLOOD returns from the circulation.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports research program related to diseases of the heart, blood vessels, lung, and blood; blood resources; and SLEEP WAKE DISORDERS. From 1948 until October 10, 1969, it was known as the National Heart Institute. From June 25, 1976, it was the National Heart and Lung Institute. Since October 1997, the NHLBI has also had administrative responsibility for the NIH Woman's Health Initiative.
Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
A type of cardiac arrhythmia with premature contractions of the HEART VENTRICLES. It is characterized by the premature QRS complex on ECG that is of abnormal shape and great duration (generally >129 msec). It is the most common form of all cardiac arrhythmias. Premature ventricular complexes have no clinical significance except in concurrence with heart diseases.
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume.
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia ...
A total of 1727 subjects who responded were randomized, 1455 to encainide, flecainide, or placebo, and 272 to moracizine or ... Flecainide, or Placebo". New England Journal of Medicine. 324 (12): 781-788. doi:10.1056/NEJM199103213241201. PMID 1900101. ... placebo) using a double-blinded design, and 4) patients having more serious arrhythmias would also be included. The drugs used ... Patients were randomized to drug therapy or placebo if they met these criteria: They had a myocardial infarction occurring six ...
... flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". N Engl J Med. 324 (12): 781-88. doi:10.1056/ ... Flecainide has been introduced into the treatment of arrhythmias in children. In the long-term, flecainide seems to be safe in ... Flecainide has a very high affinity for lung tissue and is associated with drug-induced interstitial lung disease. Flecainide ... Because of the role of both the liver and the kidneys in the elimination of flecainide, the dosing of flecainide may need to be ...
... group 2 receives vitamin X and placebo Y, group 3 receives placebo X and vitamin Y, and group 4 receives placebo X and placebo ... Anderson JL, Pratt CM, Waldo AL, Karagounis LA (1997). "Impact of the Food and Drug Administration approval of flecainide and ... Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989). "Preliminary report: effect of encainide and flecainide on ... such as a placebo or no intervention. The groups are monitored under conditions of the trial design to determine the ...
The quality of evidence for this use is poor so it is difficult to compare it to placebo or an epidural. Inhaled lidocaine can ... flecainide, disopyramide, procainamide (class I antiarrhythmic agents) Prior use of amiodarone hydrochloride Adams-Stokes ...
Karabulut AA, Sahin S, Ekşioglu M (April 1997). "Is cimetidine effective for nongenital warts: a double-blind, placebo- ... flecainide, quinidine, fluorouracil, and benzodiazepines. Cimetidine may decrease the effects of CYP2D6 substrates that are ... but more rigorous double-blind clinical trials found it to be no more effective than a placebo. Tentative evidence supports a ... men administered cimetidine exhibited a significant reduction in sperm concentration compared to placebo-treated controls [35 ...
... for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial, The ...
The quality of evidence for this use is poor so it is difficult to compare it to placebo or an epidural.[19] ... Concurrent treatment with quinidine, flecainide, disopyramide, procainamide (class I antiarrhythmic agents). *Prior use of ...
... placebo-controlled, double-blind, crossover study". British Journal of Clinical Pharmacology. 73 (3): 411-21. doi:10.1111/j. ... a placebo-controlled study". Journal of Obstetrics and Gynaecology. 5 (4): 263-264. doi:10.3109/01443618509067772. ISSN 0144- ... a placebo-controlled drug interaction study". European Journal of Clinical Pharmacology. 68 (9): 1287-94. doi:10.1007/s00228- ... or placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days (Group ...
examined much of the same data, and found that in five placebo-controlled studies, lamotrigine did not significantly differ ... placebo-controlled clinical trials". Bipolar Disorders. 10 (2): 323-33. doi:10.1111/j.1399-5618.2007.00500.x. PMID 18271912.. ... from placebo in the treatment of bipolar depression.[23] However, in a meta-analysis of these studies conducted in 2008, ... and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo". The ...
... flecainide, or moricizine were randomly assigned to receive either active drug or placebo. The use of encainide and flecainide ... and 641 were assigned to receive flecainide or its placebo (323 to active drug and 318 to placebo). After a mean follow-up of ... Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.. ... We examined the mortality and morbidity after randomization to encainide or flecainide or their respective placebo. ...
Placebo Comparator: Single dose matched placebo A single dose of placebo will be administered once via oral inhalation for 4.5 ... Placebo Comparator: Repeat dose matched placebo Two doses of placebo will be administered via oral inhalation for 4.5 minutes. ... Within each dose regimen, subjects are randomized in a 2:1 ratio to either inhaled flecainide or matched placebo. Randomization ... Within each dose regimen, subjects are randomized in a 2:1 rate to ether inhaled flecainide or matched placebo. ...
Drug: Flecainide Acetate. *Drug: Placebo. *Drug: Beta blocker. Interventional. *Vanderbilt University Medical Center ... Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia. *Catecholaminergic Polymorphic Ventricular Tachycardia. * ... Efficacy of UX007 compared to placebo as measured by reduction from randomization to week 8 in frequency of absence seizures ... Efficacy of UX007 compared to placebo as measured by reduction from randomization to week 8 in frequency of seizures. ...
Placebo Comparator: PVC Suppression then Placebo This arm will undergo attempted PVC suppression using flecainide for 28 days ... Placebo Comparator: Placebo then PVC Suppression This arm will undergo no PVC suppression using placebo for 28 days and then ... Drug: PVC Suppression using Flecainide Drug: No PVC Suppression using Placebo Phase 2 ... and then undergo no PVC suppression using placebo for 28 days.. Drug: PVC Suppression using Flecainide Flecainide will be ...
A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide ... A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide ... Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI: Efficacy and safety of flecainide acetate in the mainte- ... Van Gelder IC, Crijns HJ, Van Gilst WH, Van Wijk LM, Hamer HP, Lie KI: Efficacy and safety of flecainide acetate in the mainte- ...
Odds ratio for conversion compared with placebo (95% CI)*. Flecainide (Tambocor): class IC ... Odds ratio is expressed as the number of times conversion is more likely with drug compared with placebo. ... Odds ratio is expressed as the number of times conversion is more likely with drug compared with placebo. ... Other antiarrhythmic drugs, including quinidine, procainamide, flecainide (Tambocor), and amiodarone, may be used in patients ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N ... The US Food and Drug Administration licensed the antiarrhythmic agents encainide and flecainide for use in patients on the ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N ...
Flecainide) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... This rate was 16/315 (5.1%) for TAMBOCOR (flecainide) and 7/309 (2.3%) for the matched placebo. The average duration of ... When flecainide is given in the presence of amiodarone, reduce the usual flecainide dose by 50% and monitor the patient closely ... flecainide acetate) Tablets. DESCRIPTION. TAMBOCOR™ (flecainide acetate) is an antiarrhythmic drug available in tablets of 50, ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... Pretreatment with amiodarone, flecainide, ibutilide, propafenone, or sotalol has been shown to increase the success rate of DC ... Class Ic drugs (flecainide, propafenone) increased the mortality risk in patients with coronary artery disease during the ... However, in their study, intolerable adverse effects were more common with amiodarone than with placebo or rate-control drugs. ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... Propafenone or flecainide in addition to a beta-blockers or non-dihydropyridine calcium channel antagonists is reasonable for ... AF or atrial flutter of ≥48 hours duration: For conversion of AF of ≤7 days, agents with proven efficacy include flecainide, ... For conversion of AF lasting 7-90 days, agents with proven efficacy include amiodarone, ibutilide, flecainide, and propafenone ...
This rate was 16/315 (5.1%) for flecainide and 7/309 (2.3%) for the matched placebo. The average duration of treatment with ... When flecainide is given in the presence of amiodarone, reduce the usual flecainide dose by 50% and monitor the patient closely ... Flecainide should be started in the hospital with rhythm monitoring. Any use of flecainide in children should be directly ... When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if ...
Flecainide or amiodarone are the recommended drugs for pharmacologic cardioversion. Flecainide results in earlier and more ... Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll ... Flecainide is preferable to amiodarone for acute and chronic rhythm control. Failure of rate or rhythm control should prompt ... Flecainide can be considered for rapid conversion to sinus rhythm, either intravenously or orally, in patients without left ...
This rate was 16/315 (5.1%) for flecainide and 7/309 (2.3%) for the matched placebo. The average duration of treatment with ... This rate was 16/315 (5.1%) for flecainide and 7/309 (2.3%) for the matched placebo. The average duration of treatment with ... When flecainide is given in the presence of amiodarone, reduce the usual flecainide dose by 50% and monitor the patient closely ... Echt, D. S. (1991-03-21). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... In this situation, the next agents to be tried would be class I antiarrhythmic drugs, such as flecainide (Tambocor) and ... flecainide [Tambocor], dofetilide [Tikosyn], sotalol [Betapace], quinidine) ... flecainide [Tambocor], dofetilide [Tikosyn], sotalol [Betapace], quinidine) ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after ... lower than that of patients randomized to placebo over an average follow-up of almost 4 years (P=0.007). Patients with heart ... Placebo, amiodarone, or ICD. Nearly equal numbers of patients with coronary disease and nonischemic cardiomyopathy were ...
... flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". N Engl J Med. 324 (12): 781-88. doi:10.1056/ ... Flecainide has been introduced into the treatment of arrhythmias in children. In the long-term, flecainide seems to be safe in ... Flecainide has a very high affinity for lung tissue and is associated with drug-induced interstitial lung disease. Flecainide ... Because of the role of both the liver and the kidneys in the elimination of flecainide, the dosing of flecainide may need to be ...
March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia ...
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... CAST was then followed by CAST-II, which involved continuation of the moricizine arm of the CAST and placebo. CAST-II was ... Patients who had significant suppression of PVCs with a particular agent were then continued on that agent or on placebo. In ... The CAST-II study authors concluded that as with the other antiarrhythmic agents used in CAST (flecainide and encainide), the ...
Amiodarone therapy was evaluated in two multi-centered, randomized, double-blind, placebo-controlled trials involving 1202 ( ... an excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with encainide or flecainide (56/730) ... compared with that seen in patients assigned to matched placebo-treated groups (22/725). The average duration of treatment with ... Antiarrhythmics: The metabolism of quinidine, procainamide, flecainide can be inhibited by amiodarone. Amiodarone taken ...
Cordarone therapy was evaluated in two multi-centered, randomized, double-blind, placebo-controlled trials involving 1202 ( ... The metabolism of quinidine, procainamide, flecainide can be inhibited by amiodarone. Amiodarone taken concomitantly with ... randomized comparisons with other agents or placebo have not been possible. Reports of series of treated patients with a ... an excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with encainide or flecainide (56/730) ...
1991) mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324:781-788. and the CAST ... 1997) Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias. Jpn Heart J 38:379-385. ... 1990) A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias. Pacing Clin Electrophysiol ... In this case, the degree of ST segment elevation seemed to depend on the dose of flecainide. Case 5. (Left strip) Sinus rhythm ...
1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial ...
Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. ... had no tachycardia while taking placebo. The number with no tachycardia also increased with progressively larger flecainide ... Edward L.C. Pritchett, Steven D. DaTorre, Marc L. Platt, Sally E. McCarville, Andrina J. Hougham, Flecainide Supraventricular ... Flecainide Supraventricular Tachycardia Study Group. *↵§Address for reprints: Edward L. C. Pritchett, MD. Box 3477, Duke ...
Atrial Fibrillation diltiazem, Xarelto, propranolol, digoxin, sotalol, flecainide, More.... Atrial Flutter diltiazem, sotalol, ... There were 5 deaths, 3 in the pooled group for Rythmol SR (0.8%), and 2 in the placebo group (1.6%). In the overall database of ... Headache was relatively common also, but was not increased compared with placebo. Other reactions reported more frequently than ... In 2 randomized, crossover, placebo-controlled, double-blind trials of 60 to 90 days duration in subjects with paroxysmal ...
... or placebo, and 272 to moricizine or placebo. In April 1989, encainide and flecainide were discontinued because of increased ... Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N ... flecainide, imipramine) against placebo. The study was too small to determine whether any of these drugs had an effect on ... Flecainide. Moricizine. Encainide. Anti-Arrhythmia Agents. Voltage-Gated Sodium Channel Blockers. Sodium Channel Blockers. ...
CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia ...
  • TAMBOCOR™ (flecainide acetate) is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. (rxlist.com)
  • It has an aqueous solubility of 48.4 mg/mL at 37°C. TAMBOCOR (flecainide) tablets also contain: croscarmellose sodium, hydrogenated vegetable oil, magnesium stearate, microcrystalline cellulose and starch. (rxlist.com)
  • What are the possible side effects of flecainide (Tambocor)? (rxlist.com)
  • Use of TAMBOCOR (flecainide) for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. (rxlist.com)
  • The use of TAMBOCOR (flecainide) is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic . (rxlist.com)
  • Because of the proarrhythmic effects of TAMBOCOR (flecainide) , its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. (rxlist.com)
  • TAMBOCOR (flecainide) should not be used in patients with recent myocardial infarction . (rxlist.com)
  • Use of TAMBOCOR (flecainide) in chronic atrial fibrillation has not been adequately studied and is not recommended. (rxlist.com)
  • As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of TAMBOCOR (flecainide) favorably affects survival or the incidence of sudden death. (rxlist.com)
  • For patients with sustained VT, no matter what their cardiac status, TAMBOCOR (flecainide) , like other antiarrhythmics, should be initiated in-hospital with rhythm monitoring. (rxlist.com)
  • TAMBOCOR (flecainide) doses may be increased in increments of 50 mg bid every four days until efficacy is achieved. (rxlist.com)
  • For PAF patients, a substantial increase in efficacy without a substantial increase in discontinuations for adverse experiences may be achieved by increasing the TAMBOCOR (flecainide) dose from 50 to 100 mg bid. (rxlist.com)
  • Flecainide (Tambocor) is a class 1C antiarrhythmic drug that blocks the inflow of sodium into heart cells thereby slowing conduction through the heart. (yourhealthbase.com)
  • Doctors were overprescribing flecainide (Tambocor) for post-MI PVCs, at least up until 1989. (blogspot.com)
  • This risk is probably increased when flecainide is co-administered with other class Ic antiarrhythmics, such as encainide. (wikipedia.org)
  • The drugs studied in the review article have been in used in other settings: lidocaine both as a topical and pump-administered medication typically for shingles, and mexiletine, tocainide and flecainide as antiarrhythmics drugs, used to control irregular heartbeat by slowing nerve impulses and making heart tissue less sensitive. (news-medical.net)
  • Amiodarone and class Ic antiarrhythmics such as flecainide are also used for cardioversion, but are limited by delayed onset of action and ventricular proarrhythmia, respectively. (ahajournals.org)
  • Mortality and morbidity in patients receiving encainide, flecainide, or placebo. (nih.gov)
  • The use of encainide and flecainide was discontinued because of excess mortality. (nih.gov)
  • We examined the mortality and morbidity after randomization to encainide or flecainide or their respective placebo. (nih.gov)
  • The mechanisms underlying the excess mortality during treatment with encainide or flecainide remain unknown. (nih.gov)
  • An excessive mortality or non-fatal cardiac arrest rate was seen in patients treated with flecainide compared with that seen in patients assigned to a carefully matched placebo-treated group. (wikidoc.org)
  • Studies (notably the Cardiac Arrhythmia Suppression Trial) have shown an increased mortality when flecainide is used to suppress ventricular extrasystoles in the setting of acute myocardial infarction. (wikipedia.org)
  • In April of 1989, the Data and Safety Monitoring Board recommended that the encainide and flecainide arms of the study be discontinued because of excessive mortality in the drug arms of the trial primarily due to arrhythmia, acute MI with shock, or chronic congestive heart failure. (physionet.org)
  • CAST-II was stopped early because long-term treatment with moricizine after an MI was associated with a trend to excess mortality as compared with no treatment or placebo. (physionet.org)
  • Amiodarone may reduce sudden cardiac death, cardiac and all-cause mortality compared to placebo or no intervention in primary prevention (persons with high risk of sudden cardiac death). (essentialevidenceplus.com)
  • Flecainide was first introduced in Europe in 1982, but its acceptance in North America has been very slow with sales taking a dramatic drop (75%) after the publication of the CAST trial which showed increased mortality among patients who had suffered a heart attack prior to initiating treatment with class 1C drugs (flecainide, propafenone). (yourhealthbase.com)
  • Nevertheless, the overall safety profile of flecainide, when given to appropriately selected patients, is very favourable with a recent study finding overall mortality in flecainide-treated patients to be lower than the expected rate in the general population. (yourhealthbase.com)
  • Suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after acute myocardial infarction with encainide, flecainide, or moricizine, would decrease mortality during long-term follow-up. (acc.org)
  • In study of patients with asymptomatic, non-life-threatening ventricular arrhythmias who'd had myocardial infarctions more than 6 days but less than 2 years previously, excessive mortality or nonfatal cardiac arrest rate occurred in those treated with encainide or flecainide, compared with patients in carefully matched placebo groups. (thefreedictionary.com)
  • This study aims to critically review the literature to evaluate whether dobutamine, compared with placebo or standard care, is associated with lower mortality and a range of secondary outcomes, in patients with severe heart failure. (esicm.org)
  • The estimate of the odds ratio for mortality for patients with severe heart failure treated with dobutamine compared with standard care or placebo was 1.47 (95% confidence interval 0.98-2.21, p = 0.06). (esicm.org)
  • In the Cardiac Arrhythmia Suppression Trial, designed to test the hypothesis that suppression of ventricular ectopy after a myocardial infarction reduces the incidence of sudden death, patients in whom ventricular ectopy could be suppressed with encainide, flecainide, or moricizine were randomly assigned to receive either active drug or placebo. (nih.gov)
  • After initial qualification, patients in CAST were randomly assigned to receive encainide, flecainide, moricizine (antiarrhythmic drugs) or a placebo. (physionet.org)
  • CAST was then followed by CAST-II, which involved continuation of the moricizine arm of the CAST and placebo. (physionet.org)
  • The CAST-II study authors concluded that as with the other antiarrhythmic agents used in CAST (flecainide and encainide), the use of moricizine to suppress asymptomatic or mildly symptomatic ventricular premature complexes after MI was not only ineffective but also harmful. (physionet.org)
  • Enrollment began in June 1987 when twenty-seven clinical centers began to randomize 4,400 post-myocardial infarction patients to placebo or treatment with encainide, flecainide, or moricizine. (clinicaltrials.gov)
  • The Cardiac Arrhythmia Pilot Study (CAPS) was a randomized, double-blind trial of antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine and placebo) in 502 patients with at least 10 ventricular premature complexes/hour, 6 to 60 days after acute myocardial infarction. (nih.gov)
  • Flecainide acetate is a white crystalline substance with a pKa of 9.3. (rxlist.com)
  • The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2). (onlinejacc.org)
  • Of 1498 patients, 857 were assigned to receive encainide or its placebo (432 to active drug and 425 to placebo) and 641 were assigned to receive flecainide or its placebo (323 to active drug and 318 to placebo). (nih.gov)
  • There were no differences between the patients receiving active drug and those receiving placebo in the incidence of nonlethal disqualifying ventricular tachycardia, proarrhythmia, syncope, need for a permanent pacemaker, congestive heart failure, recurrent myocardial infarction, angina, or need for coronary-artery bypass grafting or angioplasty. (nih.gov)
  • Flecainide causes a dose-related and plasma-level related decrease in single and multiple PVCs and can suppress recurrence of ventricular tachycardia. (nih.gov)
  • In limited studies of patients with a history of ventricular tachycardia, flecainide has been successful 30% to 40% of the time in fully suppressing the inducibility of arrhythmias by programmed electrical stimulation. (nih.gov)
  • Flecainide does not usually alter heart rate, although bradycardia and tachycardia have been reported occasionally. (nih.gov)
  • Flecainide is an antiarrhythmic that is FDA approved for the {{{indicationType}}} of paroxysmal supraventricular tachycardias (PSVT) , paroxysmal atrial fibrillation / flutter (PAF) associated with disabling symptoms, sustained ventricular tachycardia (sustained VT). (wikidoc.org)
  • Flecainide is used in the treatment of many types of supraventricular tachycardias, including AV nodal re-entrant tachycardia (AVNRT) and Wolff-Parkinson-White syndrome (WPW). (wikipedia.org)
  • Among 14 patients in Group 1 who qualified for efficacy analysis, 4 (29%) had no tachycardia while taking placebo. (onlinejacc.org)
  • Among 28 patients in Group 2,2 (7%) had no tachycardia while taking placebo. (onlinejacc.org)
  • There is also evidence that flecainide suppresses palpitations, tachycardia, and episode-associated chest pain. (yourhealthbase.com)
  • In individuals suspected of having the Brugada syndrome, the administration of flecainide may help reveal the ECG findings that are characteristic of the disease process. (wikipedia.org)
  • The group of electrophysiologists, with members form France, Germany, Italy, the Netherlands and Spain, compiling this report concludes that administration of flecainide is a safe and effective option in younger AF patients without co-existing structural heart disease. (yourhealthbase.com)
  • A paradoxical increase in the ventricular rate also may occur in patients with atrial fibrillation who receive flecainide. (wikidoc.org)
  • A review of the world literature revealed reports of 568 patients treated with oral flecainide for paroxysmal atrial fibrillation/flutter (PAF). (wikidoc.org)
  • Case reports of ventricular proarrhythmic effects in patients treated with flecainide for atrial fibrillation/flutter have included increased PVCs, VT, ventricular fibrillation (VF), and death. (wikidoc.org)
  • As with other Class I agents, patients treated with flecainide for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate. (wikidoc.org)
  • Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions. (bmj.com)
  • Amiodarone may be more effective than flecainide in patients with atrial fibrillation who are refractory to type IA antiarrhythmic agents. (essentialevidenceplus.com)
  • Amiodarone is more effective than placebo in reducing atrial fibrillation recurrence. (essentialevidenceplus.com)
  • The efficacy and safety of flecainide is reported to be a treatment option in atrial fibrillation patients without co-existing structural heart disease. (yourhealthbase.com)
  • Thus, flecainide is now recommended in current guidelines as a first-line treatment option for the conversion of atrial fibrillation (AF) to normal sinus rhythm (NSR) and for the maintenance of sinus rhythm in afibbers with no heart disease and normal left ventricular function. (yourhealthbase.com)
  • Twenty-five years in the making: flecainide is safe and effective for management of atrial fibrillation. (yourhealthbase.com)
  • Some physicians routinely prescribe digoxin or a beta-blocker with flecainide to avoid the possibility of flutter-induced 1:1 conduction. (yourhealthbase.com)
  • Published and unpublished randomized or quasirandomized clinical trials were included if they compared amiodarone with placebo, digoxin, calcium-channel blockers, or no treatment in patients with AF of any cause or duration. (acpjc.org)
  • Control treatments were placebo (10 trials), no treatment (1 trial), a calcium-channel blocker (4 trials), digoxin (5 trials), and digoxin or diltiazem (1 trial). (acpjc.org)
  • Part B has a randomized, double-blind, parallel group, placebo-controlled, multi center design to evaluate the safety (including tolerability) and efficacy of inhaled flecainide compared to matched placebo in two dosing regimens. (clinicaltrials.gov)
  • The aim of the study is to compare the efficacy of flecainide, beta-blockers, sotalol, and verapamil in children with frequent PVCs, with or without asymptomatic VT. (springer.com)
  • Trials have also shown the efficacy of intravenous ibutilide, dofetilide, and procainamide, as well as oral flecainide, propafenone, and dofetilide for acute cardioversion of AF when compared with placebo. (acpjc.org)
  • The trial's efficacy criteria compared to placebo include evaluations of sleepiness, alertness and cognition. (actusnews.com)
  • Recent studies 2-4 have reported that class I antiarrhythmic drugs such as flecainide, procainamide, and ajmaline could unmask ST segment elevation in patients with "latent" Brugada syndrome. (bmj.com)
  • The metabolism of quinidine, procainamide, and flecainide can be inhibited by amiodarone. (columbuswired.net)
  • In animals and isolated myocardium, a negative inotropic effect of flecainide has been demonstrated. (nih.gov)
  • Because of the negative inotropic effects of flecainide, it should be used with caution in individuals with depressed ejection fraction, and may worsen congestive heart failure in these individuals. (wikipedia.org)
  • [1] Effect of adrenaline on survival in out-of-hospital cardiac arrest: A randomised double-blind placebo-controlled trial Jacobs IG, Finn JC, Jelinek GA, Oxer HF, Thompson PL. Resuscitation. (roguemedic.com)
  • This trial actually compared prophylactic amiodarone with placebo for the prevention of supraventricular and ventricular tachyarrhythmias in 77 patients recovering from coronary artery bypass surgery [2] . (annals.org)
  • Intravenous infusion of flecainide is highly effective in chemically converting acute-onset (less than 48 hours duration) AF and restores NSR within an hour in 95% of patients. (yourhealthbase.com)
  • A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. (thefreedictionary.com)
  • The average duration of treatment with flecainide in this study was ten months. (wikidoc.org)
  • Flecainide is also effective in maintaining NSR after conversion with only a 38% relapse rate (over a minimum 6-month follow-up) as compared to relapse rates of 58% for sotalol and 61% for propafenone. (yourhealthbase.com)
  • At 1 year from the time of randomization to blinded therapy, 95% of placebo-treated patients vs 90% of active drug-treated patients remained alive (P = .0006). (acc.org)
  • The investigators did not randomly assign patients to either propafenone or flecainide as stated by Desai and colleagues. (annals.org)
  • Patients who had significant suppression of PVCs with a particular agent were then continued on that agent or on placebo. (physionet.org)
  • However, to date, there are no studies to support the use of flecainide as first-line therapy in children with frequent PVCs or asymptomatic VT. (springer.com)
  • In particular, flecainide has been useful in the treatment of ventricular tachycardias that are not in the setting of an acute ischemic event. (wikipedia.org)
  • Flecainide has been introduced into the treatment of arrhythmias in children. (wikipedia.org)
  • Treatment of flecainide cardiac toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. (wikipedia.org)
  • Patients received flecainide in doses of 25, 50, 100 and 150 mg twice daily and placebo for 1 month treatment periods. (onlinejacc.org)
  • Noncardiac adverse experiences were the leading cause of premature study discontinuation during flecainide treatment periods (five patients in Group 1 and six patients in Group 2). (onlinejacc.org)
  • This will be a single-blind (blinded subjects) randomized cross-over study, in which each patient will receive treatment A (flecainide or placebo) for 15 months and, after a 1 week wash-out, treatment B (placebo or flecainide) for 15 months. (bioportfolio.com)
  • THN102 (modafinil/flecainide combination) is currently undergoing a Phase II clinical trial to treat a triad of non-motor symptoms (sleepiness, attention and cognitive disorders) in Parkinson's disease patients, for which no approved treatment is currently available. (actusnews.com)
  • Neither Encainide nor Flecainide should be used in the treatment of patients with asymptomatic or minimally symptomatic ventricular arrhythmia after myocardial infarction, even though these drugs may be effective initially in suppressing ventricular arrhythmia. (acc.org)
  • There is also evidence that flecainide given prior to electrical cardioversion increases the likelihood of first shocks being successful in converting the patient to NSR (65% conversion vs 30% with placebo). (yourhealthbase.com)
  • Almost all cardiac deaths not due to arrhythmia were attributed to acute myocardial infarction with shock (11 patients receiving drug and 3 receiving placebo) or to chronic congestive heart failure (4 receiving drug and 2 receiving placebo). (nih.gov)
  • There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide. (nih.gov)
  • Flecainide was included in the National Heart Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously. (wikidoc.org)
  • The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain, but at present, it is prudent to consider the risks of Class IC agents (including flecainide), coupled with the lack of any evidence of improved survival, generally unacceptable in patients without life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs. (wikidoc.org)
  • As with all other antiarrhythmic agents, there is a risk of proarrhythmia associated with the use of flecainide. (wikipedia.org)
  • The risk of proarrhythmia is not necessarily associated with the length of time an individual is taking flecainide, and cases of late proarrhythmia have been reported. (wikipedia.org)
  • Within each dose regimen, subjects are randomized in a 2:1 ratio to either inhaled flecainide or matched placebo. (clinicaltrials.gov)
  • In man, flecainide produces a dose-related decrease in intracardiac conduction in all parts of the heart with the greatest effect on the His-Purkinje system (H-V conduction). (nih.gov)
  • The mean daily dose of flecainide was 150 mg in those whoresponded. (nationalwatch.com)
  • They add that the drugs, "were safe in controlled clinical trials for neuropathic pain, were better than placebo and were as effective as other analgesics. (news-medical.net)
  • Unfortunately, that does not lead to outcomes that are better than placebo. (roguemedic.com)
  • In a retrospective clinical study in patients with CPVT we have seen improvement of ventricular ectopy on exercise tests when flecainide is added to standard therapy. (bioportfolio.com)
  • Due to the narrow therapeutic index of flecainide, physicians should be alert for signs of toxicity before life-threatening arrhythmias occur like torsades de pointes. (wikipedia.org)
  • Comparison of Cardiovascular Effects of a Novel Class Ic Antiarrhythmic Agent, NIK-244, with Those of Flecainide in Isolated Canine Heart Preparations Cross-Circulated with a Donor Dog. (nii.ac.jp)
  • There have been two studies comparing epinephrine with placebo to treat out of hospital cardiac arrest. (roguemedic.com)
  • There is still no evidence that adrenaline provides better outcomes than placebo in human cardiac arrest patients. (roguemedic.com)
  • Similarly, at 1 year, 96% of placebo-treated patients vs 93% of active drug-treated patients remained free of cardiac arrest or arrhythmic death (P = .003). (acc.org)
  • The selectivity of bisaramil for the intraventricular conduction vs the other cardiac variables was compared with that of disopyramide and flecainide. (nii.ac.jp)
  • Flecainide helps prevent electrical remodeling by slowing conduction across the myocardium and increasing the refractory period. (yourhealthbase.com)
  • P = 0.01), and 8 of noncardiac causes (3 receiving drug vs. 5 receiving placebo). (nih.gov)
  • Nonlethal events, however, were equally distributed between the active-drug and placebo groups. (nih.gov)
  • While the toxic effects of flecainide are closely related to the plasma levels of the drug, it is unfeasible to check the plasma concentration in an individual on a regular basis. (wikipedia.org)
  • However, like any drug, flecainide does have the potential for adverse effects. (yourhealthbase.com)
  • Flecainide is preferable to amiodarone for acute and chronic rhythm control. (mja.com.au)
  • Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP (1998) Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. (esicm.org)
  • Signs of flecainide toxicity include marked prolongation of the PR interval and widening of the QRS duration on the surface ECG. (wikipedia.org)
  • Since ST segment elevation with mild QRS prolongation was observed with both pilsicainide and flecainide, strong sodium channel blocking effects in the depolarisation may have been the main factors responsible for the ECG changes. (bmj.com)
  • This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days. (clinicaltrials.gov)
  • Flecainide does not undergo any consequential presystemic biotransformation (first-pass effect). (nih.gov)
  • The trial enrolled adults with suspected meningitis and randomized them to either dexamethasone 10mg IV q6hrs x4 days started 15-20 minutes before the first IV antibiotics or a placebo IV with the same administration schedule. (medicine52in52.com)
  • At 8 weeks, 15% of dexamethasone patients compared with 25% of placebo patients had an unfavorable outcome of Glasgow Outcome Scale score 1-4 (RR 0.59, 95% CI 0.37 - 0.94, p= 0.03). (medicine52in52.com)
  • Among patients with pneumococcal meningitis, 26% of dexamethasone patients compared with 52% of placebo patients had an unfavorable outcome. (medicine52in52.com)
  • Overall, death occurred in 7% of dexamethasone patients and 15% of placebo patients (RR 0.48, 95% CI 0.24 - 0.96, p = 0.04). (medicine52in52.com)
  • In pneumococcal meningitis, 14% of dexamethasone patients died, and 34% of placebo patients died. (medicine52in52.com)
  • Following oral administration, the absorption of flecainide is nearly complete. (nih.gov)
  • The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce cardiac events compared to placebo plus standard therapy in patients with Catec. (bioportfolio.com)
  • Long-term therapy with oral flecainide has been shown to significantly reduce the frequency of AF episodes with 65% of patients being responsive to therapy in the short-term and 49% responding in the long-term. (yourhealthbase.com)
  • The study consists of 2 parts (Part A and Part B). Part A has an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens. (clinicaltrials.gov)
  • The Perkins study (PARAMEDIC2) did not find a significant difference between adrenaline (epinephrine in non-Commonwealth countries) and placebo. (roguemedic.com)
  • 13 During the study, new stones formed in only 12.9% of those taking the potassium-magnesium citrate supplement, compared to 63.6% of those taking placebo. (epnet.com)
  • In an animal model, flecainide was found to directly target the molecular defect in CPVT. (bioportfolio.com)
  • We propose a 3 year prospective trial of flecainide added to standard therapy in CPVT patients with ICD's in place to test the hypothesis that flecainide will reduce ICD shocks in patients with CPVT, compared to placebo. (bioportfolio.com)
  • Over 63,000 people with heart disease died after taking encainide or flecainide because many doctors thought taking these drugs "made biological sense," but did not understand the simple need for reliable clinical trial information to confirm what seemed to "make sense" [Echt 91]. (delfini.org)